| Expression pattern: |
UP |
| Associated gene: |
IGF2BP3, CCND2 |
| Associated microRNA: |
miR-375 |
| Biological function: |
promotes CRC cell proliferation and tumorigenesis; induces cell cycle progression (G0/G1 arrest upon knockdown) |
| Molecular mechanism: |
acts as a competing endogenous RNA (ceRNA) sponging miR-375 to promote CCND2; binds IGF2BP3 to prevent CCND2 degradation/stabilize CCND2 |
| Biological pathway or process: |
proliferation (promotes); cell cycle (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
H
M
|
| Validation methods: |
Microarray; RT-qPCR; RNase R Treatment; FISH / smFISH; ISH (In Situ Hybridization); Luciferase Reporter Assay; RNA Pull-Down; RIP (RNA Immunoprecipitation); Transfection; CCK8; Colony Formation Assay; Annexin V/PI Flow Cytometry; Cell Cycle Assay; Western Blot; In Vivo Animal Model; Clinical Sample Validation; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
High expression of hsa_circ_0000231 is associated with poor prognosis (shorter OS and lower DFS) in CRC patients; potential diagnostic and therapeutic biomarker |
| Description: |
hsa_circ_0000231 is up-regulated in colorectal cancer and promotes CRC cell proliferation and xenograft tumor growth. It upregulates CCND2 by sponging miR-375 (ceRNA mechanism) and by binding the RBP IGF2BP3 to stabilize/protect CCND2 from degradation, and high circRNA expression predicts poorer survival. |
| Confidence score: |
0.8429 |